首页> 外国专利> COMPOSITION FOR STABILIZING SURVIVAL OF TRANSPLANTED HEMATOPOIETIC STEM CELL, KIT FOR OBTAINING THE COMPOSITION, METHOD OF STABILIZING SURVIVIAL OF TRANSPLANTED HEMATOPOIETIC STEM CELL, HUMAN MONOCLONAL ANTIBODY OR HUMAN POLYCLONAL ANTIBODY AND METHOD OF PRODUCING THE SAME, GENE ENCODING HUMAN MONOCLONAL ANTIBODY AND TRANSF

COMPOSITION FOR STABILIZING SURVIVAL OF TRANSPLANTED HEMATOPOIETIC STEM CELL, KIT FOR OBTAINING THE COMPOSITION, METHOD OF STABILIZING SURVIVIAL OF TRANSPLANTED HEMATOPOIETIC STEM CELL, HUMAN MONOCLONAL ANTIBODY OR HUMAN POLYCLONAL ANTIBODY AND METHOD OF PRODUCING THE SAME, GENE ENCODING HUMAN MONOCLONAL ANTIBODY AND TRANSF

机译:用于稳定移植的造血干细胞存活的组合物,用于获得该组合物的试剂盒,用于稳定移植的造血干细胞存活的方法,人单克隆抗体或人类多克隆抗体和胶体抗体的方法

摘要

[PROBLEMS] To stabilize the survival of transplanted hematopoietic stem cells by using HLA-matched activated lymphocytes. [MEANS FOR SOLVING PROBLEMS] HLA-matched activated lymphocytes in mononuclear cells separated from peripheral blood or umbilical cord blood are proliferated and activated. After separating and collecting, the HLA-matched activated lymphocytes are employed as the main component of a composition for stabilizing the survival of transplanted hematopoietic stem cells. The obtained composition is widely usable in, for example, prevention of insufficient survival of transplanted hematopoietic stem cells and therapy for promoting the survival thereof. Although the dose of the composition varies depending on the age, conditions, etc. of a patient, a humanized antibody is administered in a dose of from 0.2 to 20 mg/kg/day to mammals including humans. The composition is administered by intravenous injection either once a day (single administration or continuous administration) or intermittently 1 to 3 times in a week or once in 2 or 3 weeks.
机译:[问题]通过使用HLA匹配的活化淋巴细胞来稳定移植的造血干细胞的存活。 [解决问题的手段]从外周血或脐带血分离的单核细胞中与HLA匹配的活化淋巴细胞得以增殖和活化。分离并收集后,将HLA匹配的活化淋巴细胞用作稳定移植的造血干细胞存活的组合物的主要成分。所获得的组合物可广泛用于例如预防移植的造血干细胞存活不足和促进其存活的疗法。尽管组合物的剂量根据患者的年龄,状况等而变化,但是人源化抗体以0.2至20mg / kg /天的剂量施用于包括人在内的哺乳动物。该组合物通过每天一次(单次给药或连续给药)静脉内给药,或者每周一次间歇性地1-3次或在2或3周中一次给药。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号